NCT06550141 - Emapalumab Prevention of CAR-T Cell Associated Toxicities | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions

Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma

Interventions

DRUG

Emapalumab

An interferon gamma (IFNγ) blocking antibody

DRUG

Cyclophosphamide

Alkylating agent

DRUG

Fludarabine Phosphate

Purine antagonist antimetabolite

DRUG

Axicabtagene Ciloleucel

Autologous treatment

Trial Locations (2)

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston